-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 3rd, Coxing Zhongwei announced that the vaccine's conditional listing application had been accepted by NMPA, which took only 3 days from the time the application was submitted to the time it was approved.
Kexing Zhongwei said that its development of the new coronavirus inactivated vaccine Kelleford ® overseas phase 3 clinical trials, the safety of the vaccine is good, 14 days after the completion of two doses of vaccination, the protection of diseases caused by the new coronavirus infection (COVID-19) to meet the relevant technical standards of the World Health Organization and the National Drug Administration issued the "clinical evaluation guidelines for the new coronavirus vaccine (trial)" standard requirements.
noted that in the middle of last month, the new coronavirus inactivated vaccine was granted emergency use permits in Brazil by Brazil's National Health Supervision Agency (ANVISA).
11 January, the Indonesian Drug and Food Administration announced that it had granted emergency approval for the vaccine.
, China's State Drug Administration has approved two new crown vaccines, the first of which is the new coronavirus pneumonia inactivated vaccine (Vero cells) for Chinese organisms of the National Pharmaceutical Group.
